What Evolutia Bio does

Evolutia Bio is a contract biomanufacturing firm that develops custom enzymes, engineered microbial strains, and fermentation/downstream processes for ingredient and industrial partners. The company's underlying platform combines AI-guided enzyme diversity generation and recombination, genome-wide strain improvement, high-throughput screening, and a proprietary BioOxi™ oxidation platform, with the explicit goal of moving novel biology from laboratory demonstration to commercially viable production. Formerly operating as Willow Biosciences / Epimeron Inc, the company was acquired by Mycofeast in 2025 and now positions itself as the development-stage arm of an integrated Evolutia–Mycofeast offering that connects AI-enabled enzyme and strain engineering with Mycofeast's bench-to-pilot-to-plant translation and industrial fermentation infrastructure.

Evolutia Bio generates revenue primarily through B2B contract development services, charging milestone-based project fees that span feasibility evaluation, optimization, and scale-up phases, with the potential for ongoing royalties or shared manufacturing economics once commercial deployment is reached. Its go-to-market is consultative enterprise field sales: prospective partners engage through the company website, specify target molecules, sector, and development stage, and Evolutia evaluates whether biology offers a viable manufacturing route. Served verticals include Food & Ingredients (the primary segment), Agriculture, Pharma & Fine Chemicals, and Industrial Biomanufacturing, with the website contact form also listing Consumer Care and Flavour & Fragrance as adjacent sectors. Pricing is not publicly disclosed and engagements are scoped individually.

The company is privately held and headquartered in San Carlos, California, operating with a small team (11–50 employees) led by Managing Directors Chris Davis and Jason Lewis, alongside Senior Director of Genetic Engineering Vesna Mitchell. No funding rounds, patents, named customers, or revenue figures are disclosed in the available data, and there are no public certifications, awards, or regulatory actions on record.

Name

Evolutia Bio

Legal name

Evolutia Bio

Website

https://willowbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Evolutia Bio is a private biomanufacturing services provider that develops custom enzymes, engineered microbial strains, and fermentation processes for ingredient and industrial partners, combining AI-guided enzyme design and its BioOxi™ oxidation platform with Mycofeast's industrial fermentation and scale-up infrastructure.

Ownership category

akta.pro rank

Product category

Contract Biomanufacturing Services

akta.pro primary industry

Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM)

akta.pro secondary industries

Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids) (EUAAAIAL), Data, Digital Twin & Advanced Analytics for Biomanufacturing (AI/ML, multivariate, historian) (HLAAAJAM)

Keywords

• Custom enzyme design
• Strain engineering services
• Bioprocess development
• Fermentation process development
• Contract biomanufacturing services

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. B2B Contract Development Services: Evolutia Bio earns revenue by developing custom enzymes, engineered microbial strains, and biomanufacturing processes under contractual agreements with ingredient and industrial partners. Revenue is generated through milestone-based project fees spanning feasibility, optimization, and scale-up phases, with commercial deployment potentially unlocking ongoing royalties or manufacturing fees shared with Mycofeast.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Evolutia Bio develops custom enzymes, engineered microbial strains, and biomanufacturing processes for ingredient and industrial partners. The company combines AI-guided enzyme engineering, genome-wide strain improvement, high-throughput screening, and the proprietary BioOxi™ oxidation platform with Mycofeast's scale-up and manufacturing infrastructure to deliver a complete path from concept to commercial production.

Product overview

Evolutia Bio is a biomanufacturing solutions provider that offers a portfolio of integrated services organized around custom enzymes, strain engineering, and process development. The company operates as a unified platform combining AI-guided enzyme engineering with genome-wide strain improvement and high-throughput screening capabilities, including the proprietary BioOxi™ oxidation platform. Formerly Willow Biosciences / Epimeron Inc, acquired by Mycofeast in 2025, Evolutia Bio partners with Mycofeast to provide a complete path from concept to commercial production, serving industries including Food & Ingredients, Agriculture, Pharma & Fine Chemicals, and Industrial Biomanufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• BioOxi™: Oxidation platform for biomanufacturing processes

Products and services

• Custom Enzymes Design and optimization of enzymes for valuable and difficult chemical transformations using AI-guided diversity generation and recombination workflows, delivered to ingredient and industrial partners.
• Strain Engineering Improvement of microbial production hosts for better titer, robustness, and product profile through genome-wide engineering approaches, delivered to ingredient and industrial partners.
• Process Development Build practical biomanufacturing development workflows from screening through fermentation, downstream optimization, and scale-up readiness for ingredient and industrial partners.
• BioOxi™ Oxidation Platform Proprietary AI-enabled oxidation platform enabling bio-based oxidation reactions for the production of high-value molecules, used in biomanufacturing processes for ingredient and industrial partners.

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• MycofeastcoreStrategic or Co-development Partner · 1 January 2025Mycofeast acquired Evolutia Bio (formerly Willow Biosciences / Epimeron Inc.) in 2025, creating an integrated biomanufacturing entity. Evolutia contributes its AI-guided enzyme engineering, genome-wide strain improvement, and process development capabilities, while Mycofeast provides bench-to-pilot-to-plant translation, industrial fermentation expertise, production infrastructure, and scale-up and commercial deployment capabilities. Together they offer a complete route from concept to commercial production for ingredient and industrial partners.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Conagen: Conagen develops custom enzymes, engineered strains, and fermentation processes for food, flavor, fragrance, and pharma customers, directly overlapping Evolutia's custom enzymes and strain engineering services.
• Amyris: Amyris operates fermentation-based biomanufacturing for ingredients and specialty chemicals, sharing Evolutia's model of translating engineered strains into commercial ingredient production.
• Codexis: Codexis is a direct peer: it engineers enzymes and develops bioprocesses for pharmaceutical, food, and industrial customers using protein engineering and fermentation, closely mirroring Evolutia's core offering.

Others

• Twist Bioscience: Twist Bioscience provides synthetic DNA and DNA-based discovery tools used by enzyme engineers and synthetic biology companies, an enabler/ecosystem participant relevant to Evolutia's platform.

Broad incumbents

• Ginkgo Bioworks: Ginkgo Bioworks is a broad incumbent in synthetic biology and cell engineering, offering organism design and biomanufacturing services across multiple verticals at greater scale than Evolutia.
• Biosynth: Biosynth is a broad incumbent supplying specialty biochemicals, peptides, and custom synthesis services, an adjacent peer in the chemicals and ingredients supply chain Evolutia targets.
• Crinetics Pharmaceuticals / Novozymes / DSM-Firmenich (enzymes division): DSM-Firmenich (with its enzymes and biomanufacturing operations) is a broad incumbent producing industrial enzymes and fermented ingredients at scale, setting the competitive benchmark for Evolutia in food and industrial biomanufacturing.

Emerging players

• Culture Biosciences: Culture Biosciences is a fermentation CDMO offering bioreactor capacity and process development services, overlapping with Evolutia's process development and scale-up readiness work.
• Arzeda: Arzeda uses AI and computational protein design to engineer enzymes and pathways for chemicals and ingredients, an emerging peer in AI-guided enzyme design that overlaps with Evolutia's AI workflows.
• Bota Bio: Bota Bio is an emerging player applying synthetic biology and fermentation to produce ingredients and specialty chemicals, comparable to Evolutia's industrial biomanufacturing positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/WillowBio
• LinkedInlinkedin.com/company/evolutiabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evolutia Bio